Refine
Year of publication
Document Type
- Article (30987)
- Part of Periodical (11539)
- Book (8326)
- Doctoral Thesis (5743)
- Part of a Book (3727)
- Working Paper (3392)
- Review (2886)
- Contribution to a Periodical (2368)
- Preprint (2355)
- Conference Proceeding (1745)
Language
- German (42224)
- English (30282)
- French (1056)
- Portuguese (720)
- Croatian (302)
- Spanish (301)
- Multiple languages (257)
- Italian (195)
- mis (174)
- Turkish (148)
Has Fulltext
- yes (75982) (remove)
Is part of the Bibliography
- no (75982) (remove)
Keywords
- Deutsch (1035)
- Literatur (811)
- taxonomy (771)
- Deutschland (543)
- Rezension (495)
- new species (457)
- Frankfurt <Main> / Universität (341)
- Rezeption (325)
- Geschichte (292)
- Übersetzung (271)
Institute
- Medizin (7822)
- Präsidium (5225)
- Physik (4810)
- Wirtschaftswissenschaften (2705)
- Extern (2657)
- Gesellschaftswissenschaften (2375)
- Biowissenschaften (2209)
- Biochemie und Chemie (1982)
- Frankfurt Institute for Advanced Studies (FIAS) (1887)
- Informatik (1729)
In the title compound, C11H14O4, an intermediate for the synthesis of a new kind of estrogen receptor modulator, all non-H atoms lie on a common plane (r.m.s. deviation = 0.0472 Å). All C-C bonds in the side chain are in a trans conformation, and the hydroxyl group is also trans to the methylene chain. In the crystal structure, molecules form centrosymmetric dimers showing a head-to-head arrangement which is stabilized by O-H...O hydrogen bonds. A weak C-H...O contact is also present.
In the title compound, C12H14N22+·2Cl-, the 4,4'-dimethyl-2,2'-bipyridinium cation is essentially planar (r.m.s. deviation for all non-H atoms = 0.004 Å) and is located on a crystallographic inversion centre. The cations and chloride anions lie in planes parallel to (111) and are connected by N-H...Cl and C-H...Cl hydrogen bonds. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.003 Å; R factor = 0.036; wR factor = 0.080; data-to-parameter ratio = 14.7.
In the title compound, C27H20F6N2O2, the dihedral angles between the planes of the aromatic rings connected by the ether O atoms are 84.13 (8) and 75.06 (9)°. The crystal structure is stabilized by N-H...O and N-H...F hydrogen bonds. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.004 Å; R factor = 0.037; wR factor = 0.088; data-to-parameter ratio = 8.2.
The complete molecule of the title compound, C18H24N2O2, is generated by a crystallographic inversion centre. The torsion angles in the hexamethylene chain are consistent with an antiperiplanar conformation, whereas the conformation of the O—CH2—CH2—CH2 unit is gauche. The three-dimensional crystal packing is stabilized by N—H⋯O and N—H⋯N hydrogen bonding.
The asymmetric unit of the title compound, C23H30N2O2, contains one half-mol-ecule, with a twofold axis splitting the mol-ecule in two identical halves. The structure of the racemic mixture has been reported previously [Rivera et al. (2009>) J. Chem. Crystallogr. 39, 827-830] but the enanti-omer reported here crystallized in the ortho-rhom-bic space group P21212 (Z = 2), whereas the racemate occurs in the triclinic space group P-1 (Z = 2). The observed mol-ecular conformation is stabilized by two intra-molecular O-H⋯N hydrogen bonds, which generate rings with graph-set motif S(6). In the crystal, mol-ecules are linked via non-classical C-H⋯O inter-actions, which stack the mol-ecules along the b axis.
In the title compound, C25H36N2O2, the two tert-butyl-substituted benzene rings are inclined at an angle of 53.5 (3)° to one another. The imidazolidine ring has an envelope conformation with with one of the C atoms of the ethylene fragment as the flap. The structure displays two intra-molecular O-H⋯N hydrogen bonds that generate S(6) ring motifs. The crystal studied was a non-merohedral twin with a fractional contribution of 0.281(6) for the minor domain.
Patient therapy is based mainly on a combination of diagnosis, suitable monitoring or support devices and drug treatment and is usually employed for a pre-existing disease condition. Therapy remains predominantly symptom-based, although it is increasingly clear that individual treatment is possible and beneficial. However, reasonable precision medicine can only be realized with the coordinated use of diagnostics, devices and drugs in combination with extensive databases (4Ds), an approach that has not yet found sufficient implementation. The practical combination of 4Ds in health care is progressing, but several obstacles still hamper their extended use in precision medicine.
Murine acetaminophen-induced acute liver injury (ALI) serves as paradigmatic model for drug-induced hepatic injury and regeneration. As major cause of ALI, acetaminophen overdosing is a persistent therapeutic challenge with N-acetylcysteine clinically used to ameliorate parenchymal necrosis. To identify further treatment strategies that serve patients with poor N-acetylcysteine responses, hepatic 3′mRNA sequencing was performed in the initial resolution phase at 24 h/48 h after sublethal overdosing. This approach disclosed 45 genes upregulated (≥5-fold) within this time frame. Focusing on C5aR1, we observed in C5aR1-deficient mice disease aggravation during resolution of intoxication as evidenced by increased liver necrosis and serum alanine aminotransferase. Moreover, decreased hepatocyte compensatory proliferation and increased caspase-3 activation at the surroundings of necrotic cores were detectable in C5aR1-deficient mice. Using a non-hypothesis-driven approach, herein pro-regenerative/-resolving effects of C5aR1 were identified during late acetaminophen-induced ALI. Data concur with protection by the C5a/C5aR1-axis during hepatectomy and emphasize the complex role of inflammation during hepatic regeneration and repair.
An improved value for the lifetime of the (anti-)hypertriton has been obtained using the data sample of Pb-Pb collisions at sNN−−−√= 5.02 TeV collected by the ALICE experiment at the LHC. The (anti-)hypertriton has been reconstructed via its charged two-body mesonic decay channel and the lifetime has been determined from an exponential fit to the dN/d(ct) spectrum. The measured value, τ = 242+34−38 (stat.) ± 17 (syst.) ps, is compatible with all the available theoretical predictions, thus contributing to the solution of the longstanding hypertriton lifetime puzzle.
An improved value for the lifetime of the (anti-)hypertriton has been obtained using the data sample of Pb-Pb collisions at sNN−−−√= 5.02 TeV collected by the ALICE experiment at the LHC. The (anti-)hypertriton has been reconstructed via its charged two-body mesonic decay channel and the lifetime has been determined from an exponential fit to the dN/d(ct) spectrum. The measured value, τ = 242+34−38 (stat.) ± 17 (syst.) ps, is compatible with all the available theoretical predictions, thus contributing to the solution of the longstanding hypertriton lifetime puzzle.
The production of the hypertriton nuclei HΛ3 and H‾Λ¯3 has been measured for the first time in Pb–Pb collisions at sNN=2.76 TeV with the ALICE experiment at LHC. The pT-integrated HΛ3 yield in one unity of rapidity, dN/dy×B.R.(HΛ3→He3,π−)=(3.86±0.77(stat.)±0.68(syst.))×10−5 in the 0–10% most central collisions, is consistent with the predictions from a statistical thermal model using the same temperature as for the light hadrons. The coalescence parameter B3 shows a dependence on the transverse momentum, similar to the B2 of deuterons and the B3 of 3He nuclei. The ratio of yields S3=HΛ3/(He3×Λ/p) was measured to be S3=0.60±0.13(stat.)±0.21(syst.) in 0–10% centrality events; this value is compared to different theoretical models. The measured S3 is compatible with thermal model predictions. The measured HΛ3 lifetime, τ=181−39+54(stat.)±33(syst.)ps is in agreement within 1σ with the world average value.
The production of the hypertriton nuclei 3ΛH and 3Λ¯H¯¯¯¯ has been measured for the first time in Pb-Pb collisions at sNN−−−√ = 2.76 TeV with the ALICE experiment at LHC energies. The total yield, dN/dy ×B.R.(3ΛH→3He,π−)=(3.86±0.77(stat.)±0.68(syst.))×10−5 in the 0-10% most central collisions, is consistent with the predictions from a statistical thermal model using the same temperature as for the light hadrons. The coalescence parameter B3 shows a dependence on the transverse momentum, similar to the B2 of deuterons and the B3 of 3He nuclei. The ratio of yields S3 = 3ΛH/(3He ×Λ/p) was measured to be S3 = 0.60 ± 0.13 (stat.) ± 0.21 (syst.) in 0-10% centrality events; this value is compared to different theoretical models. The measured S3 is fully compatible with thermal model predictions. The measured 3ΛH lifetime, τ=181+54−39(stat.)±33(syst.) ps is compatible within 1σ with the world average value.
The production of the hypertriton nuclei 3ΛH and 3Λ¯H¯¯¯¯ has been measured for the first time in Pb-Pb collisions at sNN−−−√ = 2.76 TeV with the ALICE experiment at LHC energies. The total yield, dN/dy ×B.R.(3ΛH→3He,π−)=(3.86±0.77(stat.)±0.68(syst.))×10−5 in the 0-10% most central collisions, is consistent with the predictions from a statistical thermal model using the same temperature as for the light hadrons. The coalescence parameter B3 shows a dependence on the transverse momentum, similar to the B2 of deuterons and the B3 of 3He nuclei. The ratio of yields S3 = 3ΛH/(3He ×Λ/p) was measured to be S3 = 0.60 ± 0.13 (stat.) ± 0.21 (syst.) in 0-10% centrality events; this value is compared to different theoretical models. The measured S3 is fully compatible with thermal model predictions. The measured 3ΛH lifetime, τ=181+54−39(stat.)±33(syst.) ps is compatible within 1σ with the world average value.
The Karl Schwarzschild Meeting 2017 (KSM2017) has been the third instalment of the conference dedicated to the great Frankfurter scientist, who derived the first black hole solution of Einstein's equations about 100 years ago.
The event has been a 5 day meeting in the field of black holes, AdS/CFT correspondence and gravitational physics. Like the two previous instalments, the conference continued to attract a stellar ensemble of participants from the world's most renowned institutions. The core of the meeting has been a series of invited talks from eminent experts (keynote speakers) as well as the presence of plenary research talks by students and junior speakers.
List of Conference photo and poster, Sponsors and funding acknowledgments, Committees and List of participants are available in this PDF.
Purpose of the study: There is a clinical need for antiretroviral therapy (ART) regimens that simplify dosing and make adherence easier for specific patient groups such as former intravenous drug users (IVDU) receiving opiate substitution. Availability of tenofovir DF (TDF) and other once-daily (OD) agents could offer a viable OD regimen. The 3OD study was designed to evaluate the use of OD HAART in IVDU patients.
Methods: 3OD was a single-arm, multicentre, 48-weeks trial to assess efficacy, tolerability and adherence to a OD TDF-containing HAART regimen in former IVDU patients receiving opiate substitution. Of 67 patients enrolled, 27 were antiretroviral treatment naïve, 10 were virologically suppressed (<400 copies/mL), and 30 were re-starting HAART without prior virological failure. Opiate substitution was adjusted according to subject symptoms of opiate overdosing or withdrawal. Various methods were used to assess adherence: besides pill count, patients were asked to fill in a MASRI (Medication Adherence Self-Report Inventory) questionnaire and an electronic log pad diary. Calculation of adherence by pill count assumed that unreturned pills had been taken by the subjects.
Summary of results: Overall, 55% (n = 37, ITT, M = F) of patients had viral load <400 copies/mL at week 48. Using an ITT, M = E analysis, 90% (37/41) of patients reached undetectable VL (<400 copies/mL), 56% (23/41 patients) had plasma HIV-1 RNA concentrations <50 copies/mL at week 48. Only 30 patients (45%) completed the full study and the follow-up period. In 51% of patients, TDF adherence was >100% using pill count. MASRI showed adherence rates of 80–100% in 83–85% of patients; however, 15 patients never entered any data. Diary data were entered by 57 patients; diary data were entered for fewer days than patients received treatment (mean difference 113 days, calculated from treatment start and stop dates).
Conclusion: TDF in combination with other OD antiretrovirals in former IVDU patients showed comparable efficacy to that seen in the average HIV-1 infected population. However, measurement of adherence to self-administered HAART via pill count, MASRI or diary may be misleading in this population.
Background: Recent advances in 3D printing technology have enabled the emergence of new educational and clinical tools for medical professionals. This study provides an exemplary description of the fabrication of 3D‐printed individualised patient models and assesses their educational value compared to cadaveric models in oral and maxillofacial surgery.
Methods: A single‐stage, controlled cohort study was conducted within the context of a curricular course. A patient's CT scan was segmented into a stereolithographic model and then printed using a fused filament 3D printer. These individualised patient models were implemented and compared against cadaveric models in a curricular oral surgery hands‐on course. Students evaluated both models using a validated questionnaire. Additionally, a cost analysis for both models was carried out. P‐values were calculated using the Mann‐Whitney U test.
Results: Thirty‐eight fourth‐year dental students participated in the study. Overall, significant differences between the two models were found in the student assessment. Whilst the cadaveric models achieved better results in the haptic feedback of the soft tissue, the 3D‐printed individualised patient models were regarded significantly more realistic with regard to the anatomical correctness, the degree of freedom of movement and the operative simulation. At 3.46 € (compared to 6.51 €), the 3D‐printed patient individualised models were exceptionally cost‐efficient.
Conclusions: 3D‐printed patient individualised models presented a realistic alternative to cadaveric models in the undergraduate training of operational skills in oral and maxillofacial surgery. Whilst the 3D‐printed individualised patient models received positive feedback from students, some aspects of the model leave room for improvement.
Klassische Bildmanipulation spielt sich meist im Zweidimensionalen, also in der reinen Bild-ebene ab. So werden beispielsweise Objekte aus Fotos entfernt, indem die dahinterliegende Struktur nachgezeichnet wird, oder es werden mehrere Teilbilder zu einem neuen, verfälschten Motiv zusammengesetzt. Bei der sogenannten Bildretuschierung werden unschöne Bereiche übermalt, um einen besseren Gesamteindruck zu erreichen. All diese Manipulationen haben im Grunde das gleiche Ziel: Das Erstellen einer möglichst realistischen Verfälschung der darge-stellten Szene indem die eigentlich dreidimensionalen Elemente in 2D imitiert werden.
Ziel dieser Arbeit ist es, von der reinen Zweidimensionalität eines Bildes Abstand zu nehmen und ein neues Verfahren zu entwickeln, Manipulationen im wirklichen 3D-Inhalt des Fotogra-fierten vorzunehmen. Dazu wird die klassische Bildmanipulation mit aktuellen Verfahren aus dem Bereich Multi View Stereo verknüpft. In einem ersten Schritt wird aus einer Fotoserie ein 3D-Modell mit passenden Texturen erstellt, welches anschließend nach Belieben manipuliert werden kann. Diese Veränderungen werden schließlich wieder in die Originalbilder übertragen, wodurch eine 3D-unterstützte Bildmanipulation realisiert wird.
Die praktische Umsetzung des vorgestellten Verfahrens basiert teilweise auf bereits vorhan-dener Software, die mit dem Ziel der Bildmanipulation neu kombiniert und durch eigene Um-setzungen ergänzt wird. So entsteht eine funktionierende Implementierung, die den kompletten Weg vom Original bis hin zum manipulierten Bild abdeckt.
In Bone Tissue Engineering (BTE), autologous bone-regenerative cells are combined with a scaffold for large bone defect treatment (LBDT). Microporous, polylactic acid (PLA) scaffolds showed good healing results in small animals. However, transfer to large animal models is not easily achieved simply by upscaling the design. Increasing diffusion distances have a negative impact on cell survival and nutrition supply, leading to cell death and ultimately implant failure. Here, a novel scaffold architecture was designed to meet all requirements for an advanced bone substitute. Biofunctional, porous subunits in a load-bearing, compression-resistant frame structure characterize this approach. An open, macro- and microporous internal architecture (100 µm–2 mm pores) optimizes conditions for oxygen and nutrient supply to the implant’s inner areas by diffusion. A prototype was 3D-printed applying Fused Filament Fabrication using PLA. After incubation with Saos-2 (Sarcoma osteogenic) cells for 14 days, cell morphology, cell distribution, cell survival (fluorescence microscopy and LDH-based cytotoxicity assay), metabolic activity (MTT test), and osteogenic gene expression were determined. The adherent cells showed colonization properties, proliferation potential, and osteogenic differentiation. The innovative design, with its porous structure, is a promising matrix for cell settlement and proliferation. The modular design allows easy upscaling and offers a solution for LBDT.